Intuitive Surgical (ISRG) Reports Q2 Earnings: What Key Metrics Have to Say

Intuitive Surgical (ISRG) reported strong Q2 2025 results, with revenue of $2.44 billion, up 21.4% year-over-year and exceeding consensus estimates by 3.93%, while EPS of $2.19 also beat expectations by 14.06%. This robust performance was driven by significant growth across key segments, including a 28.2% increase in Systems revenue to $574.7 million and a 23.3% rise in Services revenue to $391.2 million, complemented by an expanded Da Vinci Surgical System installed base of 10,488 units. Despite the stock's recent underperformance relative to the S&P 500, ISRG maintains a Zacks Rank #2 (Buy), suggesting potential near-term outperformance.

Analysis

Intuitive Surgical (ISRG) reported a robust second quarter for 2025, significantly exceeding consensus estimates on both top and bottom lines. The company posted revenue of $2.44 billion, a 21.4% year-over-year increase that surpassed analyst expectations by 3.93%, while its EPS of $2.19 represented a substantial 14.06% beat. This performance was underpinned by broad-based strength across all key operating metrics. Notably, Systems revenue grew an impressive 28.2% year-over-year to $574.7 million, indicating strong demand for new Da Vinci surgical platforms. This was complemented by solid growth in recurring revenue streams, with Instruments and Accessories revenue up 18.5% and Services revenue up 23.3%, both ahead of estimates. The Da Vinci Surgical System installed base also expanded to 10,488 units, slightly above projections. Despite these strong fundamentals and a Zacks Rank #2 (Buy) suggesting potential near-term outperformance, the stock has significantly lagged the broader market, returning only +0.2% over the past month versus the S&P 500 composite's +5.9% gain.

Key Decisions for Investors

• Given the significant earnings beat and broad-based strength across all revenue segments, investors may view the stock's recent underperformance relative to the S&P 500 as a potential entry point.
• Monitor future reports for sustained momentum in both high-margin system sales and recurring instrument revenue, as these are the key drivers validating the company's growth trajectory.
• The disconnect between strong fundamental performance and recent stock price stagnation warrants consideration, suggesting a need to evaluate if market sentiment or other factors are weighing on the stock despite the positive results.